beyond
air
present
oppenheimer
fall
healthcare
life
sciences
medtech
summit
garden
city
globe
newswire
beyond
air
nasdaq
xair
medical
device
biopharmaceutical
company
focused
developing
inhaled
nitric
oxide
treatment
patients
respiratory
conditions
including
serious
lung
infections
pulmonary
hypertension
gaseous
treatment
solid
tumors
tumor
metastases
today
announced
steven
lisi
chairman
chief
executive
officer
beyond
air
participate
oppenheimer
fall
healthcare
life
sciences
medtech
summit
held
virtually
september
presentation
details
date
time
tuesday
september
edt
location
oppenheimer
hosting
year
event
virtually
webcast
live
access
webcast
presentation
available
oppenheimer
beyond
air
inc
beyond
air
medical
device
biopharmaceutical
company
developing
revolutionary
generator
delivery
system
uses
generated
ambient
air
deliver
precise
amounts
lungs
ventilated
patients
potential
treatment
variety
pulmonary
diseases
generate
ppm
delivery
either
continuously
fixed
amount
time
ability
either
titrate
dose
demand
maintain
constant
dose
company
currently
applying
therapeutic
expertise
develop
treatments
pulmonary
hypertension
various
settings
addition
treatments
respiratory
tract
infections
effectively
addressed
current
standards
care
beyond
air
currently
advancing
revolutionary
clinical
trials
treatment
severe
lung
infections
bronchiolitis
nontuberculous
mycobacteria
ntm
additionally
beyond
air
using
concentrations
proprietary
delivery
system
separate
target
certain
solid
tumors
setting
information
visit
nitric
oxide
nitric
oxide
powerful
molecule
naturally
synthesized
human
body
proven
play
critical
role
broad
array
biological
functions
airways
targets
vascular
smooth
muscle
cells
surround
small
resistance
arteries
lungs
currently
exogenous
inhaled
used
adult
respiratory
distress
syndrome
post
certain
cardiac
surgeries
persistent
pulmonary
hypertension
newborn
treat
hypoxemia
additionally
believed
play
key
role
innate
immune
system
vitro
studies
suggest
possesses
activity
common
bacteria
including
also
diverse
pathogens
including
mycobacteria
viruses
fungi
yeast
parasites
potential
eliminate
resistant
strains
generator
delivery
system
beyond
air
generator
delivery
system
phasic
flow
nitric
oxide
delivery
system
designated
medical
device
us
food
drug
administration
fda
ventilator
compatible
version
device
generate
ambient
air
demand
delivery
lungs
concentrations
ranging
part
per
million
ppm
ppm
system
could
potentially
replace
large
cylinders
providing
significant
advantages
hospital
setting
including
greatly
reducing
inventory
storage
requirements
improving
overall
safety
elimination
purging
steps
benefits
also
deliver
concentrations
ppm
potentially
treating
severe
acute
lung
infections
hospital
setting
bronchiolitis
chronic
refractory
lung
infections
home
setting
ntm
elimination
cylinders
beyond
air
intends
offer
treatment
home
setting
beyond
air
approved
commercial
use
beyond
air
investigational
use
beyond
air
suggesting
use
ppm
use
home
forward
looking
statements
press
release
contains
statements
concerning
inhaled
company
product
including
statements
regard
potential
regulatory
developments
potential
impact
patients
anticipated
benefits
associated
use
statements
include
statements
expectations
beliefs
intentions
regarding
product
offerings
business
financial
condition
results
operations
strategies
prospects
identify
statements
words
anticipates
expects
intends
impacts
plans
projects
believes
estimates
likely
goal
assumes
targets
similar
expressions
use
future
tense
conditional
constructions
may
could
like
fact
statements
relate
strictly
historical
current
matters
rather
statements
relate
anticipated
expected
events
activities
trends
results
date
made
statements
relate
matters
yet
occurred
statements
inherently
subject
risks
uncertainties
could
cause
actual
results
differ
materially
future
results
expressed
implied
statements
statements
predictions
reflect
views
date
made
respect
future
events
financial
performance
many
factors
could
cause
actual
activities
results
differ
materially
activities
results
anticipated
statements
including
risks
related
approach
discover
develop
novel
drugs
unproven
may
never
lead
efficacious
marketable
products
ability
fund
results
clinical
trials
obtaining
maintaining
protecting
intellectual
property
utilized
products
ability
enforce
patents
infringers
defend
patent
portfolio
challenges
third
parties
ability
obtain
additional
funding
support
business
activities
dependence
third
parties
development
manufacture
marketing
sales
distribution
products
successful
development
product
candidates
early
stages
development
obtaining
regulatory
approval
products
competition
others
using
technology
similar
others
developing
products
similar
uses
dependence
collaborators
short
operating
history
risks
identified
described
detail
risk
factors
section
company
recent
annual
report
form
filings
sec
available
website
undertake
obligation
update
policy
updating
revising
statements
except
required
applicable
law
contacts
steven
lisi
chief
executive
officer
beyond
air
slisi
